Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Felbamate
Drug ID BADD_D00871
Description Felbamate is an anticonvulsant drug used in the treatment of epilepsy. In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization). Alternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites.
Indications and Usage For use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use.
Marketing Status Prescription
ATC Code N03AX10
DrugBank ID DB00949
KEGG ID D00536
MeSH ID D000078328
PubChem ID 3331
TTD Drug ID D05KON
NDC Product Code 51525-0442; 51672-4185; 63629-1944; 0037-0431; 62559-731; 17381-554; 0037-0430; 65162-734; 43826-255; 47621-054; 42385-721; 51672-4172; 69988-0032; 51672-4186; 72578-056; 66689-825; 51525-0430; 46016-2542; 62559-730; 16714-775; 73223-003; 47781-630; 47781-627; 70771-1077; 63629-1937; 43826-256; 0121-0891; 72578-057; 65162-686; 0037-0442; 70771-1078; 51525-0431; 65162-735; 22365-007
Synonyms Felbamate | 2-Phenyl-1,3-propanediol dicarbamate | 2 Phenyl 1,3 propanediol dicarbamate | Taloxa | Felbatol | Felbamyl | ADD-03055 | ADD 03055 | ADD03055 | (3-Carbamoyloxy-2-phenyl-propyl) carbamate | W-554 | W 554 | W554
Chemical Information
Molecular Formula C11H14N2O4
CAS Registry Number 25451-15-4
SMILES C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
HepatotoxicityCytochrome P450 3A4P08684T378489606477; 9314612
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Leukopenia01.02.02.001--Not Available
Lichen planus23.03.08.001--Not Available
Livedo reticularis24.03.04.003; 23.06.05.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Lymphoma16.20.01.001; 01.12.01.001--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Mean cell volume increased13.01.05.022--Not Available
Megacolon07.02.05.002--Not Available
Menstrual disorder21.01.01.004--Not Available
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Metrorrhagia21.01.01.006--Not Available
Microcephaly15.11.02.002; 03.11.02.002--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Miosis17.02.11.002; 06.05.03.003--Not Available
Mononeuritis17.09.02.007--Not Available
Mood swings19.04.03.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myeloid leukaemia16.01.08.001; 01.10.08.001--Not Available
Nausea07.01.07.001--
Necrosis24.04.02.006; 08.03.03.001--Not Available
Neoplasm16.16.02.001--Not Available
Nephrotic syndrome20.05.01.002--
Nervousness19.06.02.003--Not Available
Non-Hodgkin's lymphoma01.17.01.001; 16.35.01.001--Not Available
Nystagmus17.02.02.006; 06.05.02.006--
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages